These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 15731739)

  • 1. Nucleoside/nucleotide reverse transcriptase inhibitor drug interactions.
    Samarasinghe YP; Boffito M; Di Perri G
    J HIV Ther; 2004 Nov; 9(4):79-86. PubMed ID: 15731739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors].
    Bonora S; Calcagno A; Gonzalez de Requena D; Bargiacchi O; Di Perri G
    Infez Med; 2006 Jun; 14(2):61-70. PubMed ID: 16891850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors.
    Weiss J; Weis N; Ketabi-Kiyanvash N; Storch CH; Haefeli WE
    Eur J Pharmacol; 2008 Jan; 579(1-3):104-9. PubMed ID: 18037401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between non-nucleoside reverse transcriptase inhibitor and nucleoside reverse transcriptase inhibitor mutations: phenotypes and mechanisms.
    Shulman NS
    Curr Opin HIV AIDS; 2007 Mar; 2(2):88-93. PubMed ID: 19372872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleoside analogue reverse transcriptase inhibitor options: a re-examination of the class.
    Hammer SM
    Top HIV Med; 2006; 14(4):140-3. PubMed ID: 17114828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
    Menéndez-Arias L
    Virus Res; 2008 Jun; 134(1-2):124-46. PubMed ID: 18272247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug transporters relevant to HIV therapy.
    Thomas SA
    J HIV Ther; 2004 Nov; 9(4):92-6. PubMed ID: 15731741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools.
    Vela JE; Miller MD; Rhodes GR; Ray AS
    Antivir Ther; 2008; 13(6):789-97. PubMed ID: 18839780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
    Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F
    Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors.
    Geretti AM
    AIDS Rev; 2006; 8(4):210-20. PubMed ID: 17219736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
    Waters LJ; Nelson MR
    Int J Clin Pract; 2005 Dec; 59(12):1452-8. PubMed ID: 16351678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ideal nucleoside/nucleotide backbone.
    Gallant JE
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S44-51. PubMed ID: 15319669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically relevant drug interactions with antiretroviral agents.
    Burger DM; Hoetelmans RM; Koopmans PP; Meenhorst PL; Mulder JW; Hekster YA; Beijnen JH
    Antivir Ther; 1997 Jul; 2(3):149-65. PubMed ID: 11322270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
    Ripamonti D; Maggiolo F
    Curr Opin Investig Drugs; 2008 Aug; 9(8):899-912. PubMed ID: 18666038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.